Research Focus

Over the past two decades starting with the full characterization of the normal human genome, scientists have begun to create a registry of specific genetic changes such as mutations, translocations and deletions that enable a cell to grow and spread uncontrollably. In identifying the “driver” DNA change that confers the malignant phenotype, scientists have successfully identified medications that specifically target the expression of the driver and in some cases, this has led to cancer remissions, long-term survival and possible cures.

Another level of attack of cancer cells has come through taking advantage of the human immune system. The immune system is capable of recognizing, targeting and curing specific cancer types. However, most tumors can evade immune attack through down regulation of T cell function through engagement of T cell check points. Antibodies directed at check points to block tumor cell engagement have resulted in long term progression free and overall survival particularly when cancer cells have a high number of mutations (high mutational burden).

Too many patients, however, continue to acquire cancers where a target is not known, and they cannot be cured with available therapies. Whole genome sequencing and analysis of the transcriptome and proteome are now within the investigative sites of Eileen Fund researchers. Our scientists are using the latest breakthrough in tools aimed to dive deeper than ever before into the root causes of the malignant phenotype so to develop new and more effective therapies for every individual regardless of their cancer type or prior therapies. Targeting mutations with small molecules, facilitating the immune response with antagonist and agonist and altering the host microbiome are all the therapy types being brought to bear in our effort.

John Theurer Cancer Center Research Division

Changing the Future of Cancer through Collaboration

Through our partnership with the National Cancer Institute’s Immunology branch, Georgetown University’s Lombardi Comprehensive Cancer Center, the Parker Institute for Cancer Immunotherapy, and Memorial Sloan Kettering, we are propelling advances in novel anticancer treatments, including immunotherapy and cellular therapies. Progress in the development, assessment, and FDA approval of these treatments is happening at an accelerating pace, and you may be able to benefit from these innovative therapies right here at John Theurer Cancer Center.